Search search Menu Home Our Products Ophthalmic Ophthalmic devices A clear vision for eye care One of the main criticalities of self-administered eye care treatments today is poor patient adherence, especially with chronic diseases. We strive to improve patient experience by providing safe and effective multidose eyedroppers for preservative-free solutions, used all over the world. All Commercially available In development/Research Tailor-made for customers Novelia Novelia® is a multi-dose closing tip system which avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment. Discover more e-Novelia e-Novelia® is the smart ophthalmic add-on which improves an already existing way of administrating ophthalmic treatments, to improve patients' adherence. Discover more Our services Integrated services from device selection to GMP manufacturing We have developed end-to-end services and expertise in ophthalmic device development, and device consulting, to complement our diverse portfolio of products to help you through every step of the journey. Discover more Early-stage Innovation Nemera provides a full understanding of the patient journey and recommends user-related activities to further optimize patients’ experience for a specific drug/device combination product. Discover more Testing services for customer formulations Thanks to our high-end laboratory facilities, we propose device plus formulation test services, as well as test methods development for our customers’ needs. Discover more FAQs What conditions are Nemera’s ophthalmic devices used for? Our systems are predominantly used for chronic pathologies requiring long-term daily use of eye drops, such as glaucoma, dry eye disease (DED), conjunctivitis, and allergies. Glaucoma is a group of eye diseases which result in damage to the optic nerve and cause vision loss, being a leading cause of global irreversible blindness. Overall, the results demonstrate that glaucoma is responsible for approximately 5.2 million cases of blindness (15% of the total burden of world blindness). Dry Eye Disease is a common multifactorial disease of the ocular surface with loss of homeostasis of the tear film and ocular symptoms, such as irritation, redness, discharge, and easily fatigued eyes. In epidemiological studies performed globally, the prevalence of dry eye disease (DED) ranges from 5 to 50 percent. Why does Novelia® have a blue tip? What is the PureFlow® system? Our product catalogue Ophthalmic Download More about Nemera Knowledge Hub Cutting-edge insights, resources, press articles, and webinars to learn more about the holistic ecosystem of drug delivery device solutions. Discover more Who we are We design and manufacture devices that maximize treatment efficacy and partner with our customers in their device strategies, to ultimately bring high-quality and safe treatment solutions to patients. Discover more Get in touch Get in touch to find out more about us, our solutions and what we can do for you. If you’re looking for job opportunities, please visit: Join Our Team First Name*: Last Name*: Company Name*: Job Title*: State: Country*: Please select... Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegowina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d'Ivoire Croatia (Hrvatska) Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France France Metropolitan French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Heard and Mc Donald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran (Islamic Republic of) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao, People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macau Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands Spain Sri Lanka St. Helena St. Pierre and Miquelon Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Virgin Islands (British) Virgin Islands (U.S.) Wallis and Futuna Islands Western Sahara Yemen Yugoslavia Zambia Zimbabwe Email*: Phone: Main Interest*: Please select... Our Services Our Products Other Channel (how did you hear about us?)*: Please select... Search Engine Social Media Website Exhibitions Press Word of Mouth Third party network Other Message*: Your personal data is intended for Nemera and its subsidiaries to process your request for information. You have rights over your personal data, such as the right to access, erase and object. For more information, see our Privacy Policy. * Required fields. LinkedIn Twitter Youtube Who We Are Privacy Policy Cookies policy Legal Policy 20 Avenue de la Gare 38290 La Verpillière - France T. +33 4 74 94 06 54 © 2021 Nemera. Website developed by Illustrate Digital